NCT00779220 - A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis | Biotech Hunter

Enrollment

152

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

February 28, 2010

Study Completion Date

March 31, 2015

Conditions

Rheumatoid Arthritis

Interventions

DRUG

placebo

Intravenous repeating dose

DRUG

methotrexate

Oral repeating dose

DRUG

ocrelizumabu 50mg

Intravenous repeating dose (50mg)

DRUG

ocrelizumabu 200mg

Intravenous repeating dose (200mg)

DRUG

ocrelizumab 500mg

Intravenous repeating dose (500mg)

Trial Locations (7)

Chugoku region, Chugoku

Chubu region, Chūbu

Hokkaido Region, Hokkaido

Kanto Region, Kanto

Kinki Region, Kinki

Kyusyu region, Kyusyu

Sikoku region, Sikoku